Thyroid hormones (THs) have a significant effect on the cardiovascular system. THs increase myocardium stretch, leading to the release of B-type Natriuretic Peptide (BNP), which is considered a diagnostic biomarker of heart failure (HF). Thyroid dysfunctions (subclinical hypothyroidism; SCH and subclinical hyperthyroidism; SCHyper) stimulate several changes in the heart by causing either diastolic or systolic left ventricular dysfunctions leading to HF. This study aims to measure the changes of B- type NP levels in cases of subclinical hypo and hyperthyroidism. The present study aims to measure the changes in B-type Natriuretic Peptide (BNP) levels in subclinical hypo and hyperthyroidism (SCH and SCHyper). A theoretical study was also conducted using a docking program to find the effectiveness of some drugs in inhibiting or promoting B-type Natriuretic Peptide (BNP). A case study was conducted in a private clinic, Mosul- Iraq, from (April 1st – Sep 1) 2021, with 25 healthy participants with normal functioning thyroids as a control group (EU). A newly diagnosed 25 SCH and 17 SCHyper patients participated in this study, considering that none of them have thyroid dysfunctions taking medicine, hypertension, heart diseases, renal failure, and pregnant women. They all were checked for Thyroid Function Tests (TFTs), Free Triiodothyronine (FT3), Free Thyroxin (FT4) and Thyroid Stimulating Hormone (TSH). The plasma level of BNP was measured in all participants of the three groups. The results showed that the plasma level of BNP was higher in SCHyper patients (10.97 pg/ml) as compared to that of SCH patients (8.09 pg/ml) and EU subjects (8.27 pg/ml). Hereby, we could state that subclinical hyperthyroidism, SCHyper, triggers BNP release. Therefore, it should be kept in mind that any high BNP levels due to SCHyper should be considered a reliable diagnostic biomarker of heart failure (HF). Keywords. Thyroid hormone(TH), Subclinical hypothyroidism(SCH), Subclinical hyperthyroidism(SCHyper), Chronic heart disease(CHD), Heart failure(HF), B-type natriuretic peptide(BNP), Docking Study.

No abstract

A study was aimed to determine the incidence of celiac disease (CD) and to make morphometric analysis of duodenal biopsy in children already diagnosed as a short stature in Mosul city. One hundred and seventy seven children aged between 3-17 years with short stature were examined. Their age, gender, serum antitransglutaminase antibody; and small intestinal biopsy were taken. The changes in the biopsy were evaluated and graded by by Corazza and Villanacci grading system. Short stature children serologically positive for celiac disease were only subjected to small intestinal biopsy. Results revealed that most predominate age group were those between 11-17 years (mean 11.8 years), with a higher male gender (107/177, 60.4%0 than female (70/177, 39.6%). Of these CD represents in 54 out of 177 children, with a grade B (b) was the predominant one (24 out from 54)(44.5%). In conclusion, short stature can be the only symptom for celiac disease in children aged between 7-11 years with higher tendency in male than female. The health significance of short stature is to subject children to intestinal biopsy for celiac disease confirmation.